Back to Top Skip to main content

Researchers will present findings at Military Health System Research Symposium

The theme of this year’s meeting is “Medical Innovation for Warfighter Readiness.” The theme of this year’s meeting is “Medical Innovation for Warfighter Readiness.”

Recommended Content:

MHSRS 2019 | Research and Innovation

Researchers from Naval Medical Research Center will discuss their latest findings during the 2018 Military Health System Research Symposium (MHSRS), Aug. 20-23. 

The scientific meeting will be held at the Gaylord Palms Resort and Convention Center in Kissimmee, Florida and will focus on the unique medical research needs of our armed forces. NMRC researchers will present their work to counter wound infections, malaria, pneumonia, arthritis, and more and how it protects the health of warfighters on and off the battlefield. 

The theme of this year’s meeting is “Medical Innovation for Warfighter Readiness,” and will feature presentations by Acting Assistant Secretary of Defense for Health Affairs, Thomas McCaffrey, Acting Deputy Assistant Secretary of Defense for Health Readiness Policy and Oversight, Terry M. Rauch, Ph.D., and Director of the Defense Health Agency, Navy Vice Adm. Raquel C. Bono, among others.

As the DoD’s premier scientific meeting, MHSRS helps to facilitate the exchange of information between almost 3,000 attendees from around the world on health care topics related to combat casualty care, rehabilitative medicine, infectious diseases, medical simulation, and the operational readiness of the warfighter.

“Our researchers are committed to conducting medical research to improve the readiness of our Sailors and Marines across the globe, and to protect our warfighters operating in harm's way," said Navy Capt. Adam Armstrong, commander, Naval Medical Research Center. 

Scientists from across the entire Navy Medicine research and development enterprise will join scientists from across the Department of Defense to share information about current research initiatives for new treatments and prevention measures for injuries and diseases that improve mission readiness. They will discuss with their military medicine colleagues and partners from academia and industry a broad range of topics during breakout and poster sessions that highlight the innovative work they’re doing, including: 

  • PfSPZ Vaccine: A Whole Organism Malaria Vaccine for Protection of Military Personnel, Travelers, and Individuals in Malaria-Endemic Regions
  • Development of Strategies to Counter Wound Infections in Maritime Environments
  • Histopathological Evidence of Multiple Organ Damage After Simulated Long-range Flight in a Swine model
  • Multi-functional Hydrogels for Advanced Wound Contact Materials: Combating Drug Resistance in Traumatic Limb Injuries

Among the many presenters, Navy Cmdr. Matthew Bradley, department head of regenerative medicine in the Operational Undersea Medicine Directorate, will introduce an updated version of the model NMRC developed to identify predictors of pneumonia in combat trauma patients.

“Pneumonia is the most common hospital acquired infection in trauma patients. As part of our ongoing iterative process, we developed a more sensitive predictive model for pneumonia, which is an important test to ensure the disease does not go undiagnosed,” said Bradley. “Advancing modeling for the development of clinical decision support tools is a huge step forward in continuing to care for the warfighter.”

Disclaimer: Re-published content may have been edited for length and clarity. Read original post.     



You also may be interested in...

DHA-PI 3200.01: Research and Development (R&D) Enterprise Activity (EA)


This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (p): a. Establishes the Defense Health Agency’s (DHA) procedures for the Deputy Assistant Director (DAD), R&D to manage and execute, on behalf of the Assistant Secretary of Defense for Health Affairs (ASD(HA)), the portion of the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation assigned to it (referred to as the “DHP Science and Technology (S&T) Program)”. The DHP S&T Program includes Budget Activities (BAs) 6.1-6.3 and 6.6. The ASD(HA) provides policy, direction, and guidance to inform planning, programming, budgeting, and execution of the DHP RDT&E appropriation in accordance with statute, regulation, and policy in Reference (a). The DAD-R&D, and Component Acquisition Executive (CAE) manage and execute DHP RDT&E Program funds aligned to them on behalf of the ASD(HA). The CAE is responsible for managing BAs 6.4, 6.5, and 6.7 funding, as well as Procurement and Operations and Maintenance funding required to support DHP-funded Acquisition Programs, regardless of acquisition activity. b. Supports the Director, DHA, in developing appropriate DHA management models to maximize efficiencies in the management and execution of DHP RDT&E-funded activities carried out by the Combatant Commands (CCMDs), Services, Uniformed Services University of the Health Sciences (USU), Defense Agencies, and other DoD Components, as applicable. c. Codifies processes to confirm DHP RDT&E funds are applied towards medical priorities and aligned to ASD(HA) policy, direction, and guidance to develop and deliver innovative medical products and solutions that increase the readiness of the DoD medical mission in accordance with Reference (a). d. Supports the following objectives of the R&D EA: (1) Increasing the quantity, quality, and pace of medical research through improved programmatic organization, processes, and oversight. (2) Ensuring DHP RDT&E funded efforts align to ASD(HA) published program guidance that provides resourcing guidance and translates national, departmental, and Service priorities into specific program objectives. (3) Verifying alignment of DHP RDT&E funds to medical priorities and to ASD(HA) policy, direction, and guidance to ensure the development and delivery of medical materiel and knowledge solutions. (4) Facilitating coordination with the CCMDs, Services, USU, Defense Agencies, and other DoD Components, as applicable, to ensure DHP RDT&E funded activities address joint medical capability gaps, and avoid unnecessary duplication.

Guidance on the Establishment of a Human Cell, Tissue, and Cellular and Tissue Based Products Program


This memorandum requests the Services resource a Human Cell, Tissue, and Cellular and Tissue Based Products (HCT/Ps) Program that complies with regulatory standards for management and oversight of HCT/Ps, according to the best fit for their Service.

Showing results 1 - 2 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.